Your Gateway to Innovative Medical Research with a Ready Pool of Patients for Seamless Clinical Trials

With a vast, pre-existing patient database and cutting-edge digital infrastructure, Meditrial ensures efficient, patient-ready clinical trials, setting a new standard in research excellence.

At Meditrial, we believe that truly impactful healthcare is built on a foundation of trust, advanced technology, equal access, and a commitment to excellence. Our values guide every study we conduct and every patient interaction, ensuring that integrity and innovation go hand-in-hand in advancing medical research.

Dedicated to Breakthroughs in Medical Research for a Healthier Future.

Our mission is driven by a vision where every individual has access to safe, life-changing treatments. Through rigorous research standards, ethical practices, and a patient-first approach, we continually strive to push the boundaries of what’s possible in healthcare. Together with our dedicated team of researchers, healthcare professionals, and support staff, we are committed to setting new benchmarks in clinical trials and medical care for underprivileged communities across South Africa.

Meditrial’s primary focus will be on conducting clinical trials in Primary Healthcare conditions and Vaccines, leveraging the existing patient base from our parent company, Desmed Clinics. The top 15 medical conditions currently observed at Desmed Clinics, which will guide our initial focus areas, are:

While these areas represent our core focus, we continuously adapt our research to address the most prevalent conditions seen in our clinics each month. Additionally, our established relationships with numerous regional specialists allow us to collaborate on trials across a broad range of therapeutic areas, enhancing our ability to innovate and address diverse health issues.

Dr Jessica Fryer is a Pietermaritzburg native who graduated from the University of Pretoria where she fostered a love for medicine. During her tenure as a Community Service Office in rural KZN she saw the desperate need for the equalization in the provision of health care and the advancement of medicine. She worked as a Sub Investigator at the Limpopo Clinical Research Initiative where these two goals were being addressed through research. Dr Fryer has worked on a number of COVID-19, Influenza and Respiratory Syncytial Virus related vaccine and treatment studies across all age groups. She has also been involved in HIV treatment and cardiovascular outcome trials. Her passion is in providing world-class care, quality data, and helping to bring a brighter tomorrow.

Dr Mohammed Bassa, a native of KwaZulu-Natal, graduated from Shandong University and later served as a Medical Intern at RK Khan Hospital and a Community Service Officer at Wentworth Hospital. During his tenure, he became acutely aware of the pressing need to deliver advanced medical care to disadvantaged populations. Dr Bassa then co founded Desmed Clinics which boasts 5 Clinics , he further honed his skills as a Sub-Investigator at Synapta Research Centre, where he contributed to notable studies, including the Celldex inducible urticaria trial and the Spero complicated Urinary Tract Infection study. His passion lies in providing exceptional care to underprivileged communities, driving his commitment to bridging the healthcare gap.

Dr Ebrahim Desai, a native of KwaZulu-Natal, graduated from Shandong University and completed his medical internship at King Edward VIII Hospital (Victoria Mxenge Hospital). During his time at King Edward, he was introduced to research by professors from the University of KwaZulu-Natal Medical School, which sparked his realization that clinical trials can profoundly impact the lives of previously underprivileged communities. Dr. Desai then served his community service at the South African National Defence Force, where he played a pivotal role as Director of the COVID-19 office for the KZN region during the pandemic.

In 2021, Dr Desai founded Desmed Clinics, which has rapidly expanded to five clinics, serving approximately 5,000 patients monthly. He further refined his skills as a Sub-Investigator at Synapta Research Centre, contributing to notable studies such as the Celldex inducible urticaria trial and the Spero complicated Urinary Tract Infection study. Dr. Desai is now dedicated to improving the lives of the less fortunate and previously underprivileged populations, driven by his passion for delivering exceptional care and making a meaningful difference.

Leave us your details and we will contact you shortly.